United States
Germany
Japan
United Kingdom
China
Meioc (NM_001127576) Mouse Tagged ORF Clone Lentiviral Particle
CAT＃: MR212947L3V
- LentiORF®
-
Lenti ORF particles, Gm1564 (Myc-DDK-tagged) - Mouse predicted gene 1564 (Gm1564), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 14,820.00
货期*
详询
规格
Product images
经常一起买 (2)
Specifications
| Product Data | |
| Product Name | Meioc (NM_001127576) Mouse Tagged ORF Clone Lentiviral Particle |
| Synonyms | Gm663; Gm1564 |
| Vector | pLenti-C-Myc-DDK-P2A-Puro |
| ACCN | NM_001127576 |
| ORF Size | 2895 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(MR212947).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_001127576.2, NP_001121048.1 |
| RefSeq Size | 4577 bp |
| RefSeq ORF | 2898 bp |
| Locus ID | 268491 |
| Gene Summary | Is required for meiosis completion in both male and female germ cells. Confers stability to numerous meiotic mRNAs in gonads allowing proper initiation and progression into meiosis prophase I. The function may involve YTHDC2 and is independent of induction by retinoic acid (RA). Maintains an extended meiotic prophase I by properly promoting the transition from a mitotic to a meiotic cell cycle program by binding transcripts through its interaction with YTHDC2 that regulate the mitotic cell cycle (PubMed:28380054).[UniProtKB/Swiss-Prot Function] |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
You may also need
Customer
Reviews
Loading...
